Takeda Pharmaceutical Company
Search results
Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.
Jan 8, 2019 · OSAKA, JAPAN, January 8, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its acquisition of Shire plc (“Shire”), becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan.
Jan 19, 2024 · Five years ago this month, Takeda Pharmaceuticals completed a $62 billion acquisition of Shire — one of the largest deals in pharma history. The anniversary has triggered a fresh wave of scrutiny over its value and mixed bag of results.
May 8, 2018 · Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry.
Dec 5, 2018 · Takeda Pharmaceutical has won shareholder approval to finance its £46bn purchase of Shire, paving the way for Japan’s largest corporate takeover and the creation of a global drugmaker with...
Shire completes combination with Baxalta creating the global leader in rare diseases and highly specialized conditions. June 3, 2016. Share. Combined company expected to deliver double-digit compound annual top-line growth with over $20 billion in annual revenues by 2020.
May 8, 2018 · Takeda Pharmaceutical will pay $62 billion to acquire rare disease biotech Shire, securing on Tuesday a deal that will create one of the world’s largest drugmakers by sales and transform the 237-year-old Japanese company.
